Antiva Biosciences

Developer of therapeutic drugs for sexually transmitted diseases. It offfer therapeutics that improve health outcomes for patients suffering from diseases caused by HPV and other viruses. Its lead drug program is aimed at intervening before lesions in the cervix and anus become cancerous. The lead molecule ABI-1968 is a topical therapeutic for the treatment of oncogenic HPV infection and pre-cancerous moderate to high-grade cervical intraepithelial neoplasias.